Agennix has posted a net loss of EUR11.2m for the third quarter 2010, or EUR0.54 loss per diluted share, compared to net loss of EUR2.14m, or EUR0.29 loss per diluted share, for the comparable period in 2009.
Agennix has posted a revenue of EUR153,000 for the nine months ended 30 September 2010, compared to EUR274,000 for the year ago period.
For the nine months ended 30 September 2010, Agennix has posted a net loss of EUR19.38m, or EUR0.94 loss per diluted share, compared to net loss of EUR10.61m, or EUR1.44 loss per diluted share, for the year ago period.
Agennix chief financial officer Torsten Hombeck said that their top development priorities continue to be the advancement of oral Talactoferrin for the treatment of non-small cell lung cancer and severe sepsis.
"We have carefully reviewed all of our programs and plans for the year ahead and have made important decisions and changes to ensure that we can achieve meaningful results from these two programs using our existing financial resources," Hombeck said.
"With the recent successful completion of our financing that netted proceeds of approximately EUR76m, we believe we now have sufficient resources to get to top-line data in our FORTIS-M trial with Talactoferrin in non-small cell lung cancer and to conduct the Phase 2 portion of our planned Phase 2/3 trial with Talactoferrin in severe sepsis."
Agennix is a biopharmaceutical company engaged in the development of new therapies that have the potential to improve the length and quality of life of critically ill patients in areas of major unmet medical need.